Live Breaking News & Updates on சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம்

Stay updated with breaking news from சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Don't focus on herd immunity, vaccination should be comprehensive: COVID panel expert

Don t focus on herd immunity, vaccination should be comprehensive: COVID-19 panel expert
Toggle share menu
Advertisement
Don t focus on herd immunity, vaccination should be comprehensive: COVID-19 panel expert
Associate Professor Lim Poh Lian, an infectious diseases outbreak expert, dressed in personal protective equipment. (Photo courtesy of A/Prof Lim)
28 Dec 2020 10:25AM)
Share this content
Bookmark
SINGAPORE: Rather than aim for a certain percentage of the population to be inoculated to achieve COVID-19 herd immunity, Singapore should vaccinate as many people as possible.
In an interview with CNA, Associate Professor Lim Poh Lian, who is on the Expert Committee for COVID-19 Vaccination, said that it s a mistake to focus on percentages when it comes to COVID-19 vaccination. ....

Tan Tock Seng Hospital , Singapore General , United States , Lucas Yap Keyuan , National Centre For Infectious Disease , United Nations Global Health Crises Taskforce , Response Network , Ministry Of Health , World Health Organization , Traveller Health Vaccination Clinic , Singapore Health Sciences Authority , Drug Administration Of The United States , Expert Committee , Associate Professor Lim Poh Lian , Prime Minister Lee Hsien Loong , Assoc Prof Lim , Traveller Health , Vaccination Clinic , Tan Tock Seng , National Centre , Infectious Disease , High Level Isolation Unit , Global Outbreak Alert , Prof Lim , Humanity Awards , Lucas Yap ,

FDA approves osimertinib for treatment of non-small cell lung cancer

FDA approves osimertinib for treatment of non-small cell lung cancer
medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.

Richard Pazdur , Oncology Center , Us Department Of Health , Human Services , Singapore Health Sciences Authority , Australian Therapeutic Goods Administration , Brazilian Health Regulatory Agency , Office Of Oncologic Diseases , Health Canada , Oncologic Diseases , Drug Evaluation , Orphan Drug , Breakthrough Therapy , Project Orbis , Health Sciences Authority , புற்றுநோயியல் மையம் , எங்களுக்கு துறை ஆஃப் ஆரோக்கியம் , மனிதன் சேவைகள் , சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம் , அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள் , ஆரோக்கியம் கனடா , புற்றுநோயியல் நோய்கள் , மருந்து மதிப்பீடு , ஆர்ஃபந் மருந்து , திருப்புமுனை சிகிச்சை , ப்ராஜெக்ட் ஆர்‌பிஸ் ,

FDA approves first adjuvant treatment for patients with non-small cell lung cancer

FDA approves first adjuvant treatment for patients with non-small cell lung cancer
Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
Today s approval of Tagrisso demonstrates how additional research on therapies approved in later stages of cancer can eventually improve treatment options for patients in earlier stages. With this approval, patients may be treated with this targeted therapy in an earlier and potentially more curative stage of non-small cell lung cancer.
Richard Pazdur, M.D., Director, FDA s Oncology Center of Excellence and Acting Director, Office of Oncologic Diseases in the FDA s Center for Drug Evaluation and Research ....

Richard Pazdur , Emily Henderson , Oncology Center , Us Department Of Health , Human Services , Drug Administration , Singapore Health Sciences Authority , Australian Therapeutic Goods Administration , Brazilian Health Regulatory Agency , Health Canada , Office Of Oncologic Diseases , Acting Director , Oncologic Diseases , Drug Evaluation , Orphan Drug , Breakthrough Therapy , Project Orbis , Health Sciences Authority , எமிலி ஹென்டர்சன் , புற்றுநோயியல் மையம் , எங்களுக்கு துறை ஆஃப் ஆரோக்கியம் , மனிதன் சேவைகள் , சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம் , ஆரோக்கியம் கனடா , அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள் , நடிப்பு இயக்குனர் ,

FDA approves osimertinib as adjuvant therapy for non-small cell lung

On December 18, 2020, the Food and Drug Administration approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Efficacy was demonstrated in a randomized, double-blind, placebo-controlled trial (ADAURA, NCT02511106) in patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC who had complete tumor resection, with or without prior adjuvant chemotherapy. Eligible patients with resectable tumors (stage IB – IIIA) were required to have predominantly non-squamous histology and EGFR exon 19 deletions or exon 21 L858R mutations identified prospectively from tumor tissue in a central laboratory by the cobas® EGFR Mutation Test. A total of 682 patients were randomized (1:1) to receive osimertinib 80 mg orally once daily or ....

Australian Therapeutic Goods Administration , Singapore Health Sciences Authority , Brazilian Health Regulatory Agency , Oncology Center , Astrazeneca Pharmaceuticals , Drug Administration , Health Canada , Project Orbis , Health Sciences Authority , Real Time Oncology Review , Assessment Aid , Expedited Programs , Serious Conditions Drugs , Watch Reporting System , சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம் , புற்றுநோயியல் மையம் , ஆரோக்கியம் கனடா , ப்ராஜெக்ட் ஆர்‌பிஸ் , ஆரோக்கியம் அறிவியல் அதிகாரம் , ரியல் நேரம் புற்றுநோயியல் விமர்சனம் , மதிப்பீடு உதவி , துரிதப்படுத்தப்பட்டது ப்ரோக்ர்யாம்ஸ் , தீவிரமானது நிபந்தனைகள் மருந்துகள் , வாட்ச் புகாரளித்தல் அமைப்பு ,

Covid-19 vaccine: Why some groups of people should wait

December 18, 2020
Determining whether a vaccine is safe for certain groups of people needs to be guided by data from vaccine studies.
The Straits Times
SINGAPORE - There are some groups of people who should wait to receive a Covid-19 vaccine, including those with a history of severe allergic reactions, said a panel of experts on Thursday (Dec 17).
Serious allergies usually refer to people who, in response to a specific stimulus such as a bee sting or medication, experience swelling around the mouth, eyes or face, have difficulty breathing or experience a serious drop in blood pressure, said Associate Professor Lim Poh Lian, the director of the high-level isolation unit at the National Centre for Infectious Diseases. ....

New York , United States , United Kingdom , Eng Eong , Aashish Pal , Biontech Covid , Salma Khalik , Singapore Health Sciences Authority , New York Times , National Centre For Infectious Diseases , Health Ministry , Associate Professor Lim Poh Lian , National Centre , Straits Times , Prof Lim , Professor Ooi Eng Eong , Merck Sharp , Health Sciences Authority , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஆஷிஷ் நண்பா , சல்மா காழிக் , சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம் , புதியது யார்க் முறை , தேசிய மையம் க்கு தொற்று நோய்கள் ,